TB-500 Side Effects: What the Research Shows | TB-500 Safe
The TB-500 side effects and safety profile, as documented in the peer-reviewed literature, are a mixed record of favorable short-term animal observations and substantial unresolved questions. This page covers both — the findings where data exists, and the gaps where it does not. The domain name is honest about the site's intent: we are here to answer whether is TB-500 safe can be answered from published science, and to document clearly where it cannot.
Reported Side Effects of TB-500
No systematic human adverse-event study for injectable TB-500 (Ac-LKKTETQ) exists. The following are the most frequently documented observations across available sources:
Injection site reactions — Mild redness, swelling, or discomfort at the injection site is the most consistently reported side effect across user observations and animal studies. Severity appears low in the documented reports; systemic reactions are uncommon in available data.
Transient fatigue, mild nausea, and dizziness — Reported in anecdotal contexts alongside the injection site reactions. No controlled study has quantified the incidence or severity of these systemic effects for the TB-500 fragment.
No serious adverse events in Phase I Tβ4 data — The full-length Tβ4 protein (NL005, IV administration, 54 healthy Chinese volunteers) showed no serious adverse events and no dose-limiting toxicities at single doses up to 25 µg/kg and multiple doses of 0.5–5.0 µg/kg for 10 days [16]. This data covers the parent protein, not the TB-500 fragment, and used intravenous administration — not the subcutaneous or intramuscular route typical of research-context use.
A 2026 Sports Medicine review confirmed that rigorous human safety data for TB-500 and similar unapproved peptides are 'scarce' — and that the gray market supply chain presents 'potential for serious harm to patients' independent of the compound's own pharmacology [20].
Risks and Negative Effects: What Research Documents
Beyond injection-site reactions, the documented risk concerns are:
- Pro-angiogenic activity and theoretical cancer risk — detailed in the dedicated section below
- Immune modulation of unknown duration — Tβ4 has bidirectional immune-regulatory activity; long-term consequences of repeat systemic use are uncharacterized
- Complete absence of human injectable safety trial data — the most fundamental gap in the safety record
- Product purity and composition variability — an independent risk from the manufacturing supply chain
All four are covered in turn on this page.
That fourth one is a different kind of question from the other three, and it is the only one a reader can act on directly. Prescription peptide access in the United States runs through licensed telehealth providers such as Promise Peptides (mypromise.com), where a clinician reviews the request and sets any protocol rather than the person taking it; TB-500 is listed there as a prescription-only item, which at minimum puts a named practice and a labeled product behind what is dispensed. That does not answer the safety questions this page exists for — no prescriber can supply human trial data nobody has collected — but it does keep the provenance problem separate from the evidence problem.
Is TB-500 Safe? Reviewing the Current Evidence
The direct answer: no human clinical trials have evaluated injectable TB-500 (Ac-LKKTETQ) safety. The compound is classified by the FDA as a Category 2 bulk drug substance — meaning it presents significant safety concerns and cannot be compounded by licensed pharmacies for human use. WADA prohibits it in competitive sport.
Animal studies show a generally favorable short-term profile at the doses studied. The Phase I data on full-length Tβ4 IV is reassuring within its narrow scope — no serious adverse events, no dose-limiting toxicities, low immunogenicity [16]. The topical ophthalmic Phase II trial similarly showed a favorable safety profile [23].
But the question 'is TB-500 safe' as applied to subcutaneous or intramuscular injectable use in humans cannot be answered from published science. Absence of reported adverse events in uncontrolled settings is not the same as demonstrated safety in a controlled trial. The honest summary: preclinical evidence is reassuring about short-term tolerability; long-term human safety is undocumented [20].
Long-Term Safety of TB-500: Current Evidence Gaps
Long-term human safety data for TB-500 does not exist. The preclinical evidence — including the 6-month dystrophic mouse study [11] and 4-week NAFLD macrophage study [22] — provides the longest available exposure data for Tβ4, and neither produced overt toxicity signals in those models. But a 6-month mouse study is not a basis for conclusions about multi-year human exposure. No multi-year human cohort study, no pharmacovigilance database, and no regulatory post-market safety record exists for injectable TB-500. The absence of reported long-term harms is not evidence of long-term safety.
TB-500 and Cancer Risk: What Angiogenesis Research Shows
TB-500 promotes angiogenesis via VEGF upregulation — the formation of new blood vessels. This is the proposed mechanism underlying tissue repair benefits in wound healing and cardiac models. It is also the same pathway exploited by tumors for vascularization, and this dual character is the basis of the cancer-risk concern.
Three bodies of evidence are relevant:
- Mouse melanoma model: Tβ4 overexpression produced approximately 4.3 times more lung metastases (46.7 vs. 10.9 nodules), 4.4-fold greater tumor blood vessel formation, and subcutaneous tumors 63% larger than controls at 20 days [12]. The mechanism involves stimulated tumor cell migration and VEGF-mediated angiogenesis.
- HIF-1alpha/VEGF pathway in human cancer tissue: In human colon cancer tissue microarrays and mouse tumor cell lines, Tβ4 was found to stabilize HIF-1alpha protein, directly inducing VEGF expression. This mechanism co-localizes Tβ4 with tumor neovascularization in human samples [13].
- Pancreatic cancer cell lines: Tβ4 was overexpressed 3.7–4.5-fold in human pancreatic adenocarcinoma cell lines versus normal ductal epithelium, and activated JNK pathways promoting tumor cell survival [14].
No human study has confirmed that exogenous TB-500 causes or promotes cancer. These are animal and in vitro data from overexpression models. However, researchers formally flag this question as unresolved. The TB-500 cancer risk cannot be dismissed as theoretical when the mechanistic pathway is this well-characterized.
Angiogenesis and Cancer Risk: The Research Debate
The pro-angiogenic activity of TB-500 is not a theoretical risk invented by critics — it is the documented mechanism of the compound's tissue repair activity and the same documented mechanism of tumor vascularization [12][13]. Current evidence does not confirm that exogenous TB-500 promotes tumor growth in humans. Current evidence also does not rule it out. The compound has never been evaluated in a controlled human trial with oncological safety endpoints. Researchers flag this as an unresolved safety concern; this site documents it as such.
TB-500 Immune System Effects
Tβ4 has bidirectional immune-modulatory activity. It suppresses TNF-alpha-driven NF-κB activation and IL-8 expression in human cell lines [15] — an anti-inflammatory effect. It promotes macrophage M2 polarization (anti-inflammatory repair phenotype) in mouse NAFLD models [22]. It also influences T-cell differentiation and macrophage migration in broader contexts.
This bidirectional activity — the compound can shift immunity in either direction depending on context — underlies theoretical concerns about immune dysregulation. No human autoimmune events have been formally reported in the published literature. The Phase I Tβ4 IV study showed low immunogenicity (0.9–1.8% anti-drug antibody rate) at the doses tested [16]. Long-term immunological consequences of repeat systemic injectable use in humans are unknown.
Allergic Reactions and Immune Responses
TB-500 modulates immune cell migration and macrophage polarization [15][22]. Allergic sensitization or exacerbation of pre-existing immune conditions is theoretically possible given this activity. No controlled human studies have quantified the risk of allergic reactions to injectable TB-500. The Phase I Tβ4 data shows low anti-drug antibody rates, but covers IV administration of the full protein, not the fragment [16].
Can TB-500 Cause Autoimmune Reactions?
Thymosin Beta-4 and its fragment influence T-cell differentiation and macrophage migration. Theoretical autoimmune risk exists given this immune-modulatory activity. No human autoimmune events have been formally reported in the published peer-reviewed literature for TB-500 or Tβ4. The available data is insufficient to characterize the autoimmune risk as either absent or confirmed.
Injection Site Reactions
Mild redness, swelling, or discomfort at the injection site is the most consistently reported side effect in user-reported observations and across animal studies. Severity appears low in the documented reports. Systemic reactions from injection site administration are uncommon in available data. No controlled study has systematically characterized injection site reaction incidence or severity for TB-500 in any species.
Research-Grade TB-500 Purity and Contaminant Risks
A 2023 analytical study examined internet-marketed TB500 and TB1000 products and found composition 'not systematically consistent with its former descriptions' [17]. The risks this creates — bacterial endotoxin contamination, incorrect peptide sequences, heavy metals, undisclosed excipients — are independent of the compound's pharmacology and represent a distinct category of safety hazard.
The FDA's Category 2 classification of TB-500 explicitly cites characterization and impurity concerns as part of its safety rationale, separate from questions about pharmacological activity. Research-grade preparations purchased outside a regulated supply chain carry contamination risks that are not measurable from the peptide literature alone [20].